News headlines about Caladrius Biosciences (NASDAQ:CLBS) have trended somewhat positive recently, AlphaOne Sentiment Analysis reports. The research firm, a subsidiary of Accern, identifies negative and positive media coverage by reviewing more than twenty million blog and news sources. AlphaOne ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Caladrius Biosciences earned a media sentiment score of 0.10 on AlphaOne’s scale. AlphaOne also assigned news coverage about the biotechnology company an impact score of 0 out of 100, indicating that recent media coverage is extremely unlikely to have an effect on the stock’s share price in the near future.
These are some of the media stories that may have impacted AlphaOne’s scoring:
- Caladrius Biosciences Inc (CLBS) PT Set at $7.00 by HC Wainwright (americanbankingnews.com)
- CALADRIUS BIOSCIENCES, INC. (NASDAQ:CLBS) Files An 8-K Completion of Acquisition or Disposition of Assets (4-traders.com)
- Shares in Focus: Caladrius Biosciences, Inc. (NASDAQ:CLBS) – Business Daily (oxfordbusinessdaily.com)
- Caladrius Biosciences Closes the Sale of its Remaining Interest in PCT to Hitachi Chemical for $75 Million (finance.yahoo.com)
- Shares in View: Caladrius Biosciences, Inc. (NASDAQ:CLBS) – Geneva Journal (genevajournal.com)
Shares of Caladrius Biosciences (NASDAQ:CLBS) traded down 4.29% on Friday, reaching $4.91. The company had a trading volume of 45,754 shares. Caladrius Biosciences has a 52-week low of $2.65 and a 52-week high of $7.79. The company has a 50-day moving average price of $4.82 and a 200-day moving average price of $4.35.
Caladrius Biosciences (NASDAQ:CLBS) last issued its quarterly earnings results on Thursday, May 18th. The biotechnology company reported ($1.12) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.72) by $0.40. The business had revenue of $7.92 million during the quarter, compared to analyst estimates of $9.50 million. Caladrius Biosciences had a negative net margin of 183.36% and a negative return on equity of 270.38%. Equities research analysts expect that Caladrius Biosciences will post ($3.14) EPS for the current year.
CLBS has been the subject of several analyst reports. HC Wainwright set a $7.00 target price on Caladrius Biosciences and gave the stock a “buy” rating in a research report on Monday, March 20th. Zacks Investment Research downgraded Caladrius Biosciences from a “hold” rating to a “sell” rating in a research report on Wednesday, May 3rd.
Caladrius Biosciences Company Profile
Caladrius Biosciences, Inc, formerly NeoStem, Inc, through its subsidiary, PCT, LLC, a Caladrius Company (PCT), provides development and manufacturing services to the cell therapy industry (which includes cell-based gene therapy). PCT specializes in cell and cell-based gene therapies. PCT offers development and manufacturing capabilities, quality systems, cell and tissue processing, logistics, storage and distribution and engineering solutions to clients with therapeutic candidates at all stages of development.
Receive News & Ratings for Caladrius Biosciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Caladrius Biosciences Inc and related companies with MarketBeat.com's FREE daily email newsletter.